Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease
Clinical Journal of the American Society of Nephrology Aug 12, 2018
Edwards ME, et al. - Given tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively, in the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, researchers investigated if the reduction related to the tolvaptan treatment was sustained, cumulative, and likely to delay the need for kidney replacement therapy. Of 128 patients included, 20 participated in short-term studies or received placebo only. A follow-up for up to 11.2 years (average 4.6 years) was carried out. Findings demonstrated that the reduction in the annual rate of eGFR decline in patients treated with tolvaptan was sustained, compared with controls. Between the two groups, an increasing separation of eGFR values was seen over time.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries